CN1333020A - 生化物质作为组合物用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病 - Google Patents
生化物质作为组合物用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病 Download PDFInfo
- Publication number
- CN1333020A CN1333020A CN01124330A CN01124330A CN1333020A CN 1333020 A CN1333020 A CN 1333020A CN 01124330 A CN01124330 A CN 01124330A CN 01124330 A CN01124330 A CN 01124330A CN 1333020 A CN1333020 A CN 1333020A
- Authority
- CN
- China
- Prior art keywords
- compositions
- mcg
- biochemical substances
- magnesium
- smooth muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 210000000329 smooth muscle myocyte Anatomy 0.000 title claims abstract description 20
- 210000000056 organ Anatomy 0.000 title claims abstract description 11
- 201000010099 disease Diseases 0.000 title claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 22
- 230000008602 contraction Effects 0.000 title description 3
- 239000000463 material Substances 0.000 title description 3
- 239000000126 substance Substances 0.000 claims abstract description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 11
- 239000011668 ascorbic acid Substances 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- -1 ascorbic acid compound Chemical class 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims description 6
- 150000001483 arginine derivatives Chemical class 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 3
- OUTZUBHQVHHZEL-UHFFFAOYSA-N 2-aminoacetic acid;molybdenum Chemical compound [Mo].NCC(O)=O OUTZUBHQVHHZEL-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 241001672694 Citrus reticulata Species 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 229940093797 bioflavonoids Drugs 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 239000011692 calcium ascorbate Substances 0.000 claims description 3
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 3
- 229940047036 calcium ascorbate Drugs 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 3
- 235000021466 carotenoid Nutrition 0.000 claims description 3
- 150000001747 carotenoids Chemical class 0.000 claims description 3
- 239000013522 chelant Substances 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 229920002770 condensed tannin Polymers 0.000 claims description 3
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 claims description 3
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 3
- 229940011405 cupric glycinate Drugs 0.000 claims description 3
- 229960002104 cyanocobalamin Drugs 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- 235000010389 delta-tocopherol Nutrition 0.000 claims description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 3
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229940074358 magnesium ascorbate Drugs 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 229940004916 magnesium glycinate Drugs 0.000 claims description 3
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 claims description 3
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 235000018192 pine bark supplement Nutrition 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229940106796 pycnogenol Drugs 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002718 selenomethionine Drugs 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- 229940021056 vitamin d3 Drugs 0.000 claims description 3
- 229940071566 zinc glycinate Drugs 0.000 claims description 3
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 239000002446 δ-tocopherol Substances 0.000 claims description 3
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical group Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims description 2
- 235000019766 L-Lysine Nutrition 0.000 claims description 2
- 235000013878 L-cysteine Nutrition 0.000 claims description 2
- 239000004201 L-cysteine Substances 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 150000002681 magnesium compounds Chemical class 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 229940091250 magnesium supplement Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 abstract description 14
- 208000009205 Tinnitus Diseases 0.000 abstract description 9
- 231100000886 tinnitus Toxicity 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 6
- 208000010412 Glaucoma Diseases 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 238000012076 audiometry Methods 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及生化物质组合物用于预防和治疗由人体器官平滑肌收缩而引起的影响健康的疾病,所述疾病如高血压、哮喘、青光眼和耳鸣。
Description
技术领域
本发明总的来说涉及预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病。
发明背景
许多疾病的起因仍然是不清楚的。在这些不清楚起因的疾病中,最常见的疾病包括高血压、哮喘、青光眼和耳鸣。对于高血压来说,医学领域最有名的教科书之一“Harrison’s Principles of Internal Medicine”中描述了大约有90%患者的病因是不清楚的。世界范围内,数亿人患有这些影响健康的疾病并且因不能有效地治疗这些影响健康的疾病而对社会造成的经济损失是不可估量的。
世界范围内有数百万人患有支气管哮喘(哮喘)。在其后期阶段,哮喘是导致不能工作并与社会脱离的衰弱性疾病。这种疾病的起因仍然是不清楚的,即使已涉及到过敏源、遗传素因和心理学因素。该疾病的一般发病机理是肺中换气通道(支气管)梗阻而不能进入进行氧合作用的肺泡。然而,触发这种梗塞而引起哮喘的细胞机理仍然是不清楚的。
耳鸣是听力减弱的一种形式,大多数情况下是突然发生并且没有任何预兆。估计世界范围内有一百万以上的患者患有耳鸣和相关的听力减弱。这种疾病的起因和发病机理是不清楚的并且目前还没有改善耳鸣患者的听力的有效疗法。因此,许多这样的患者数年和数十年遭受听力受损并且对工作和社会生活能力常常产生有害的影响。
假定在不同器官中发生的各种明显不同的影响健康的疾病是因相同类型的细胞(称作平滑肌细胞)的生化机能障碍引起的。这种类型的肌细胞对有意识的控制不敏感,例如这与臂或腿的肌肉相反。所以,平滑肌细胞的合适代谢功能是在所有平滑肌细胞起重要功能的器官中避免使健康成问题的关键。
对于哮喘来说,假定可发现一般的细胞机制。细支气管和肺泡通道的壁包含一层平滑肌细胞。如果这些细胞收缩-与触发无关-这些肺管的直径会减小,导致换气量和氧合作用减少。因此,哮喘和/或梗塞性肺疾病患者的典型症状将发生。
对于耳鸣和听力减弱来说,可想得到的是听力减弱是由平滑肌细胞的痉挛引起的,平滑肌细胞形成使血液供应给内耳和介导听觉信号的神经细胞的血管内层。进一步假定耳毛细血管中这些平滑肌细胞的痉挛是由这些细胞最佳代谢功能必需的辅酶和其他生物能量分子的缺乏引起的。
在科学文献中没有发现对该概念的任何更早的描述。
对细胞的代谢和某些生化化合物在维持其合适功能的作用方面有了最新的进展。所以,纠正平滑肌细胞代谢的机能障碍是预防和治疗不同器官中各种影响健康的疾病的关键。
进一步发现细胞机能障碍可由某些需要在三羧酸循环(称作Krebs-循环)、呼吸链和平滑肌细胞其他代谢功能中用作辅酶的生化化合物的缺乏引起的。潜在的可预防和治疗的影响健康的疾病包括但不限于下列器官和疾病:
血管、肺、眼、尿-生殖道、胃肠道
高血压、心绞痛、耳鸣、阳萎、哮喘和其他形式的梗塞性肺疾病、青光眼和其他形式的眼压增加、月经前综合征、不孕症、输尿管和尿道痉挛、呃逆、胃痉挛、胆汁管痉挛。
发明概述
所以本发明的一个目的是给予患有包括但不限于上述影响健康疾病的患者一种生化物质组合物,所述生化物质由各种维生素、各种氨基酸和各种微量元素的化合物组成。
本发明的另一目的是给予患者生化物质组合物,组合物由至少一种选自抗坏血酸、可药用抗坏血酸盐和/或其混合物的抗坏血酸化合物组成。
本发明的另一目的是给予患者生化物质组合物,组合物由一种抗坏血酸化合物和至少一种选自精氨酸盐酸盐、可药用精氨酸盐和/或其混合物的精氨酸化合物组成。
本发明另一目的是给予患者生化物质组合物,组合物由抗坏血酸化合物、精氨酸化合物和至少一种选自镁或可药用镁盐和/或其混合物的镁化合物组成。
本发明的再一目的是给予患者下列生化物质的治疗组合物(不考虑这些加入成分的剂量):
抗坏血酸、棕榈酸抗坏血酸酯、β-,γ-,δ-生育酚混合物、β-胡萝卜素、生物素、抗坏血酸钙、柠檬酸钙、甘氨酸钙、类胡萝卜素混合物(α-类胡萝卜素(Alpha-Carot.)、叶黄素、zeea-、隐黄质)、胆钙化醇、甘氨酸铬、柑桔生物类黄酮、辅酶Q10、甘氨酸铜、氰钴胺素、d-α-生育酚、d-泛酸钙、磷酸二钙、叶酸、肌醇、L-精氨酸、L-肉碱、L-半胱氨酸、L-赖氨酸、L-脯氨酸、L-硒代蛋氨酸、抗坏血酸镁、柠檬酸镁、甘氨酸镁、锰螯合物、甘氨酸钼、烟酸、烟酰胺、钾螯合物、pycnogenol、pyrodoxine、核黄素、硫胺素、甘氨酸锌。
本发明的另一目的是给予患者生化物质组合物,而这些配方是以片剂、丸剂、注射剂、输注剂、吸入剂、栓剂或其他可药用载体和/或释放方式提供给患者的。
针对上述几种影响健康的疾病即高血压、哮喘和耳鸣进行这一构思的临床试验。
用这些生化物质组合物进行治疗导致至少部分平滑肌细胞明显松驰,导致大动脉(如,主动脉)动脉直径的增加而降低血压,增加中间大小动脉(如,冠状动脉)的动脉直径而使心绞痛减少,导致小动脉和毛细血管(如,耳动脉)直径的增加而改善听力,松驰肺细支气管和肺泡平滑肌细胞导致导气管直径增加而使哮喘症状减弱,松驰眼的导管系统导致如泪管直径的增加而减小眼压从而降低青光眼和视觉缺失的危险,松驰输卵管和子宫的平滑肌细胞导致肌组织松驰而改善生育力并减弱PMS症状,松驰胆管、输尿管和尿道的平滑肌细胞增加导管的直径而降低由胆结石或肾结石引起的痉挛危险。
已经公开了本发明的优选实施方案,仅以举例说明的方式提供下列实施例而不以任何方式限制本发明。
实施例
以该实施例所示物质的每日单位量给予患者下列生化物质的组合物:
生化物质 | 单位 | 量 |
抗坏血酸 | mg | 680 |
棕榈酸抗坏血酸酯 | mg | 620 |
β-,γ-,δ-生育酚混合物 | mg | 22 |
β-胡萝卜素 | I.U. | 1665 |
生物素 | mcg | 65 |
抗坏血酸钙 | mg | 1050 |
柠檬酸钙 | mg | 200 |
甘氨酸钙 | mg | 35 |
类胡萝卜素混合物(α-类胡萝卜素、叶黄素、zea-、隐黄质) | mcg | 50 |
胆钙化醇 | I.U. | 130 |
甘氨酸铬 | mcg | 10 |
柑桔生物类黄酮 | mg | 650 |
辅酶Q10 | mg | 7 |
甘氨酸铜 | mcg | 330 |
氰钴胺素 | mcg | 20 |
d-α-生育酚 | I.U. | 230 |
d-泛酸钙 | mg | 40 |
磷酸二钙 | mg | 15 |
叶酸 | mcg | 90 |
肌醇 | mg | 35 |
L-精氨酸 | mg | 790 |
L-肉碱 | mg | 35 |
L-半胱氨酸 | mg | 35 |
L-赖氨酸 | mg | 110 |
L-脯氨酸 | mg | 110 |
L-硒代蛋氨酸 | mcg | 20 |
抗坏血酸镁 | mg | 1050 |
柠檬酸镁 | mg | 400 |
甘氨酸镁 | mg | 40 |
锰螯合物 | mcg | 1300 |
甘氨酸钼 | mcg | 4 |
烟酸 | mg | 10 |
烟酰胺 | mg | 35 |
钾螯合物 | mg | 20 |
pycnogenol | mg | 7 |
pyrodoxine | mg | 10 |
核黄素 | mg | 7 |
硫胺素 | mg | 7 |
甘氨酸锌 | mg | 7 |
然而,可改变该实施例生化物质组合物中的各个成分,不同于所使用的处方并且不考虑其量,只要80%以上成分与所述物质相同。而且,每日提供的各组分的量可不低于实施例所示量的10%并且不高于1000%。
本发明的构思在预期的临床研究中用8名哮喘患者来试验。这些患者按日剂量接受上表所列的生化化合物4个月。在该研究的开始和结束时,测量每个患者的肺体积。研究期间,哮喘患者的肺体积以超过20%的平均值增加。该研究的最有意义的结果是对于那些具有最低基线体积的患者来说,肺体积增加百分数高得多,这表明该治疗对于患有严重哮喘和严重呼吸损伤的患者来说是非常有价值的,显示在附图1中。
本发明的构思在预期的临床研究中用18名耳鸣患者以4个月的期限来试验。听力通过测听术来进行客观评价。测听术测量的前/后结果显示在附图2中。
证明:5名患者的听力很少或没有提高(0-10分贝[dB]),8名患者有提高10到20dB,两名患者在20到30dB之间,两名患者在30到40dB之间,并且一名患者听力提高40到50dB。
到现在为止,将组合物给予危及或患有至少部分由其身体器官平滑肌细胞收缩而引起的影响健康的疾病的患者是显而易见的。尽管公开了优选的实施方案和实施例,但可以理解本发明不以任何方式受此限制而是通过下文的权利要求及其等效物来定义的。
Claims (8)
1、生化物质组合物用于预防和治疗由人体器官平滑肌细胞收缩引起的影响健康的疾病,组合物由维生素、氨基酸和可药用微量元素组成。
2、生化物质组合物用于预防和治疗至少部分由人体器官平滑肌细胞收缩引起的影响健康的疾病,组合物由至少一种选自抗坏血酸、可药用抗坏血酸盐和/或其混合物的抗坏血酸化合物组成。
3、权利要求2的生化物质组合物的用途,组合物具有至少一种选自精氨酸盐酸盐、可药用精氨酸盐和/或其混合物的精氨酸化合物。
4、权利要求2和3的生化物质组合物的用途,组合物具有至少一种选自镁或可药用镁盐和/或其混合物的镁化合物。
5、上述权利要求生化物质组合物的用途,其中上述权利要求成分的组合是用下列一种或多种生化物质共同提供的并且不考虑这些加入成分的剂量:
生化物质
单位
量
抗坏血酸
mg
680
棕榈酸抗坏血酸酯
mg
620
β-,γ-,δ-生育酚混合物
mg
22
β-胡萝卜素
I.U.
1665
生物素
mcg
65
抗坏血酸钙
mg
1050
柠檬酸钙
mg
200
甘氨酸钙
mg
35
类胡萝卜素混合物(α-类胡萝卜素、叶黄素、zea-、隐黄质)
mcg
50
胆钙化醇
I.U.
130
甘氨酸铬
mcg
10
柑桔生物类黄酮
mg
650
辅酶Q10
mg
7
甘氨酸铜
mcg
330
氰钴胺素
mcg
20
d-α-生百酚
I.U.
230
d-泛酸钙
mg
40
磷酸二钙
mg
15
叶酸
mcg
90
肌醇
mg
35
L-精氨酸
mg
790
L-肉碱
mg
35
L-半胱氨酸
mg
35
L-赖氨酸
mg
110
L-脯氨酸
mg
110
L-硒代蛋氨酸
mcg
20
抗坏血酸镁
mg
1050
柠檬酸镁
mg
400
甘氨酸镁
mg
40
锰螯合物
mcg
1300
甘氨酸钼
mcg
4
烟酸
mg
10
烟酰胺
mg
35
钾螯合物
mg
20
pycnogenol
mg
7
pyrodoxine
mg
10
核黄素
mg
7
硫胺素
mg
7
甘氨酸锌
mg
7
mg=毫克mcg=微克I.U.=国际单位
6、上述权利要求的生化物质组合物的用途,其中所使用配方的各个成分有80%以上相同,不考虑它们的量。
7、上述权利要求的生化物质组合物的用途,其中每日所给的各个成分的量不低于权利要求5各个成分量的10%并且不高于1000%。
8、上述权利要求的生化物质组合物的用途,其中该配方是以片剂、丸剂、注射剂、输注剂、吸入剂、栓剂或其他可药用载体和/或释放方式提供给患者的。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00112811A EP1163904B1 (en) | 2000-06-16 | 2000-06-16 | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium |
EP00112811.5 | 2000-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1333020A true CN1333020A (zh) | 2002-01-30 |
CN1245973C CN1245973C (zh) | 2006-03-22 |
Family
ID=8168995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011243309A Expired - Fee Related CN1245973C (zh) | 2000-06-16 | 2001-06-15 | 生化物质在制备用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病的药物中的用途 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1163904B1 (zh) |
JP (1) | JP2002047183A (zh) |
KR (1) | KR100793573B1 (zh) |
CN (1) | CN1245973C (zh) |
AT (1) | ATE323479T1 (zh) |
AU (1) | AU780906C (zh) |
BR (1) | BR0103256A (zh) |
CA (1) | CA2350713C (zh) |
CZ (1) | CZ20012178A3 (zh) |
DE (1) | DE60027415T2 (zh) |
DK (1) | DK1163904T3 (zh) |
ES (1) | ES2258426T3 (zh) |
HK (1) | HK1043947A1 (zh) |
HU (1) | HUP0102489A2 (zh) |
IL (1) | IL143697A (zh) |
NO (1) | NO20013004L (zh) |
PL (1) | PL348097A1 (zh) |
PT (1) | PT1163904E (zh) |
RU (1) | RU2280441C2 (zh) |
SK (1) | SK285454B6 (zh) |
TR (1) | TR200101673A2 (zh) |
UA (1) | UA77147C2 (zh) |
ZA (1) | ZA200104931B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687204A (zh) * | 2016-04-15 | 2016-06-22 | 石家庄东华金龙化工有限公司 | 一种甘氨酸金属螯合物复合物及其制备方法 |
CN106213522A (zh) * | 2016-08-05 | 2016-12-14 | 郑家福 | 营养保健品 |
CN108685754A (zh) * | 2018-07-30 | 2018-10-23 | 郑州兰茜生物工程有限公司 | 一种用于耳鸣及具有健耳舒耳功能的滴耳剂 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1163904B1 (en) * | 2000-06-16 | 2006-04-19 | Rath, Matthias, Dr. med. | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium |
US6576634B1 (en) * | 2000-07-07 | 2003-06-10 | N.V. Nutricia | Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality |
US6372264B1 (en) * | 2000-08-24 | 2002-04-16 | Gusty Winds Corporation | Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium |
AU2001287917B2 (en) * | 2000-09-22 | 2007-02-08 | Mars Incorporated | Food supplement |
UA77660C2 (en) * | 2000-10-03 | 2007-01-15 | Compositions and methods for reducing plasma lipoprotein a level in human | |
AU2003239154B2 (en) * | 2002-01-31 | 2007-02-01 | Chemstop Pty Ltd | Process for the preparation of a nutrient formulation |
AUPS019802A0 (en) * | 2002-01-31 | 2002-02-21 | Chemstop Pty Ltd | Nutrient formulation |
GB0202900D0 (en) | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
US20050238693A1 (en) * | 2002-05-20 | 2005-10-27 | Chemstop Pty Ltd. | Process for the preparation and activation of susbstances and a means of producing same |
WO2004017955A1 (en) * | 2002-08-22 | 2004-03-04 | Vasopharm Biotech Gmbh | L-arginine containing pharmaceutical composition |
US9655966B2 (en) * | 2002-08-28 | 2017-05-23 | Kedar N. Prasad | Micronutrient formulations for radiation applications |
WO2004069822A1 (ja) * | 2003-02-05 | 2004-08-19 | Santen Pharmaceutical Co., Ltd. | ステロイド副作用抑制組成物 |
WO2004073623A2 (en) * | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
EP1628658A4 (en) * | 2003-05-30 | 2007-09-05 | Matthias Rath | FUNCTIONAL COMPOSITION AND METHOD FOR INHIBITING CONTRACTION OF SMOOTH MUSCLE CELLS |
WO2005094770A1 (en) * | 2004-03-30 | 2005-10-13 | Unilever Plc | Skin lightening compositions comprising vitamines and flavonoids |
FR2884691B1 (fr) * | 2005-04-21 | 2007-07-20 | Formquest Ltd | Complement alimentaire comprenant une combinaison d'agents antioxydants et d'agents energisants utile comme aide a la fertilite chez l'homme et chez la femme |
FR2884692B1 (fr) * | 2005-04-21 | 2009-08-14 | Formquest Ltd | Complement alimentaire comprenant une association d'agents antioxydants et de carnitine, obtenue par synthese endogene ou exogene, comme aide a la fertilite chez l'homme et chez la femme |
US7754700B2 (en) | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
EP1854453B1 (de) * | 2006-05-12 | 2011-02-16 | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG | Lagerstabile wässrige Zusammensetzungen, umfassend eine Magnesiumverbindung und L-Carnitin |
EP1862163A1 (de) * | 2006-05-12 | 2007-12-05 | Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG | L-Carnitin zur Kristallisationsverzögerung |
RU2315612C1 (ru) * | 2006-08-29 | 2008-01-27 | Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" | Средство для лечения заболеваний глаз |
WO2011033884A1 (ja) * | 2009-09-18 | 2011-03-24 | 明治乳業株式会社 | 筋拘縮予防剤 |
AT510810B1 (de) * | 2010-12-09 | 2017-09-15 | Gonadosan Gmbh | Kombinationspräparat zur verbesserung der weiblichen fertilität |
JP2013049670A (ja) * | 2011-08-04 | 2013-03-14 | Fancl Corp | アスコルビン酸製剤 |
WO2015199537A1 (en) * | 2014-06-24 | 2015-12-30 | Dedraf Holding B.V. | New mineral composition |
CN104688774A (zh) * | 2015-02-17 | 2015-06-10 | 胡梨芳 | 包含手性异构化合物的赖氨酸磷酸氢钙药物组合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
US5650418A (en) * | 1990-06-04 | 1997-07-22 | Therapy 2000 | Therapeutic lysine salt composition and method of use |
US5278189A (en) * | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
US5198465A (en) * | 1991-06-19 | 1993-03-30 | Dioguardi Francesco S | Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen |
GB2268871A (en) * | 1992-07-04 | 1994-01-26 | Bio Nutritional Health Service | Composition for use as a food or food supplement |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5626883A (en) * | 1994-04-15 | 1997-05-06 | Metagenics, Inc. | Ascorbic acid compositions providing enhanced human immune system activity |
EP0891771A1 (en) * | 1997-07-08 | 1999-01-20 | Health Now, Inc. | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases |
WO1999051252A1 (en) * | 1998-04-03 | 1999-10-14 | The Daily Wellness Company | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
GB9922751D0 (en) * | 1999-09-27 | 1999-11-24 | Kenton Corp Limited | A pharmaceutical composition for stabilising atherosclerotic plaques |
EP1163904B1 (en) * | 2000-06-16 | 2006-04-19 | Rath, Matthias, Dr. med. | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium |
-
2000
- 2000-06-16 EP EP00112811A patent/EP1163904B1/en not_active Expired - Lifetime
- 2000-06-16 DK DK00112811T patent/DK1163904T3/da active
- 2000-06-16 PT PT00112811T patent/PT1163904E/pt unknown
- 2000-06-16 ES ES00112811T patent/ES2258426T3/es not_active Expired - Lifetime
- 2000-06-16 DE DE60027415T patent/DE60027415T2/de not_active Expired - Fee Related
- 2000-06-16 AT AT00112811T patent/ATE323479T1/de not_active IP Right Cessation
-
2001
- 2001-06-12 IL IL143697A patent/IL143697A/en not_active IP Right Cessation
- 2001-06-13 BR BR0103256-9A patent/BR0103256A/pt not_active Application Discontinuation
- 2001-06-13 SK SK823-2001A patent/SK285454B6/sk unknown
- 2001-06-15 CZ CZ20012178A patent/CZ20012178A3/cs unknown
- 2001-06-15 ZA ZA200104931A patent/ZA200104931B/xx unknown
- 2001-06-15 UA UA2001064163A patent/UA77147C2/uk unknown
- 2001-06-15 HU HU0102489A patent/HUP0102489A2/hu unknown
- 2001-06-15 CA CA002350713A patent/CA2350713C/en not_active Expired - Fee Related
- 2001-06-15 NO NO20013004A patent/NO20013004L/no not_active Application Discontinuation
- 2001-06-15 TR TR2001/01673A patent/TR200101673A2/xx unknown
- 2001-06-15 PL PL01348097A patent/PL348097A1/xx unknown
- 2001-06-15 CN CNB011243309A patent/CN1245973C/zh not_active Expired - Fee Related
- 2001-06-15 RU RU2001116855/15A patent/RU2280441C2/ru not_active IP Right Cessation
- 2001-06-15 KR KR1020010033746A patent/KR100793573B1/ko not_active IP Right Cessation
- 2001-06-15 JP JP2001181658A patent/JP2002047183A/ja not_active Ceased
- 2001-06-15 AU AU51942/01A patent/AU780906C/en not_active Ceased
-
2002
- 2002-07-30 HK HK02105586A patent/HK1043947A1/xx not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687204A (zh) * | 2016-04-15 | 2016-06-22 | 石家庄东华金龙化工有限公司 | 一种甘氨酸金属螯合物复合物及其制备方法 |
CN105687204B (zh) * | 2016-04-15 | 2018-05-25 | 石家庄东华金龙化工有限公司 | 一种甘氨酸金属螯合物复合物及其制备方法 |
CN106213522A (zh) * | 2016-08-05 | 2016-12-14 | 郑家福 | 营养保健品 |
CN108685754A (zh) * | 2018-07-30 | 2018-10-23 | 郑州兰茜生物工程有限公司 | 一种用于耳鸣及具有健耳舒耳功能的滴耳剂 |
Also Published As
Publication number | Publication date |
---|---|
NO20013004D0 (no) | 2001-06-15 |
DE60027415T2 (de) | 2006-10-19 |
TR200101673A2 (tr) | 2002-02-21 |
CN1245973C (zh) | 2006-03-22 |
PL348097A1 (en) | 2001-12-17 |
IL143697A0 (en) | 2002-04-21 |
HUP0102489A2 (hu) | 2003-11-28 |
KR100793573B1 (ko) | 2008-01-14 |
ATE323479T1 (de) | 2006-05-15 |
CA2350713A1 (en) | 2001-12-16 |
ZA200104931B (en) | 2001-12-20 |
CA2350713C (en) | 2007-01-16 |
KR20010113499A (ko) | 2001-12-28 |
BR0103256A (pt) | 2002-03-12 |
SK8232001A3 (en) | 2002-01-07 |
AU780906C (en) | 2006-04-27 |
EP1163904B1 (en) | 2006-04-19 |
HK1043947A1 (en) | 2002-10-04 |
AU5194201A (en) | 2001-12-20 |
CZ20012178A3 (cs) | 2002-04-17 |
ES2258426T3 (es) | 2006-09-01 |
UA77147C2 (en) | 2006-11-15 |
NO20013004L (no) | 2001-12-17 |
IL143697A (en) | 2006-12-10 |
PT1163904E (pt) | 2006-07-31 |
DE60027415D1 (de) | 2006-05-24 |
RU2280441C2 (ru) | 2006-07-27 |
SK285454B6 (sk) | 2007-01-04 |
JP2002047183A (ja) | 2002-02-12 |
DK1163904T3 (da) | 2006-08-14 |
EP1163904A1 (en) | 2001-12-19 |
AU780906B2 (en) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1245973C (zh) | 生化物质在制备用于预防和治疗因人体器官中平滑肌细胞收缩而引起的影响健康的疾病的药物中的用途 | |
US6686340B2 (en) | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells | |
Aversa et al. | We are addicted to vitamins C and EA review | |
Lizardi-Cervera et al. | Hepatic encephalopathy: a review | |
Robinson et al. | Effects of nifedipine on resistance vessels, arteries and veins in man. | |
Ernst et al. | Therapeutic interventions to lower plasma fibrinogen concentration | |
MXPA03002964A (es) | Composiciones y metodos para reducir lipoproteina a de plasma y factores de riesgo de enfermedades cardiovasculares. | |
IE882740L (en) | Preservative system for ophthalmic formulations | |
KR20070100721A (ko) | 오르니틴 및 페닐아세테이트 또는 페닐부티레이트를 포함한간성 뇌병증 치료용 조성물 | |
INGEMANSSON | Clinical observations on ten cases of methanol poisoning with particular reference to ocular manifestations | |
Levin et al. | Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome | |
Aggarwal et al. | Intravascular hemolysis in aluminium phosphide poisoning | |
Salahudeen et al. | Cisplatin induces N-acetyl cysteine suppressible F2-isoprostane production and injury in renal tubular epithelial cells. | |
Schwaiblmair et al. | Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency–three-year follow-up | |
CN116173147B (zh) | 芳香植物精油在制备治疗或预防高尿酸血症组合物中的应用 | |
Teo et al. | Effect of bile on vitamin B12 absorption. | |
Miyamoto et al. | Present role of stereotactic thalamotomy for parkinsonism: retrospective analysis of operative results and thalamic lesions in computed tomograms | |
GB2600668A (en) | Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection. | |
PT1060959E (pt) | Composição para a prevenção de doenças do músculo liso, compreendendo ascorbato, argenina e magnésio | |
Zucconi et al. | Sleep impairment by diethyldithiocarbamate in rat. Protective effects of pre-conditioning and antioxidants | |
Yuanwen et al. | Unveiling the Deadly Effects of Hydrogen Cyanamide Poisoning: A Case Report | |
WO2023096617A1 (en) | Use of aurantiamide acetate in the treatment of hypertension | |
Giuffrida | Vascular Diseases and HBO | |
Fortunately | Alpha-Lipoic Acid (Thioctic Acid): My Experience With This Outstanding Therapeutic Agent | |
US20060172951A1 (en) | Age related macular degeneration and cutaneous signs of mercury toxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060322 |